McKesson Reports Strong FY26 Results, Authorizes $7.7B Share Repurchase, and Details Medical-Surgical Segment Separation

summarizeSummary

McKesson reported robust fiscal year 2026 financial results, including double-digit revenue and EPS growth, alongside an expanded $7.7 billion share repurchase authorization and detailed plans for the strategic separation of its Medical-Surgical Solutions segment with a $1.25 billion investment from Apollo.

check_boxKey Events

• Strong Fiscal Year 2026 Financial Performance

  McKesson reported a 12% increase in revenues to $403.43 billion, a 45% rise in net income attributable to McKesson Corporation to $4.76 billion, and a 49% surge in diluted EPS to $38.38 for the fiscal year ended March 31, 2026, confirming robust growth across its segments.

• Expanded Share Repurchase Program

  The Board authorized an additional $5.0 billion for common stock repurchases on April 29, 2026, bringing the total authorization to $7.7 billion. The company repurchased $4.8 billion in common stock during fiscal 2026.

• Strategic Medical-Surgical Segment Separation

  McKesson detailed its intention to separate the Medical-Surgical Solutions segment into an independent company. As part of this strategy, Apollo Funds will acquire a 13% minority ownership interest for approximately $1.25 billion in convertible preferred equity.

• Significant Acquisitions and Divestitures

  The company completed the acquisition of an 80% controlling interest in PRISM Vision for $875 million and a 70% controlling interest in Core Ventures for $2.5 billion, expanding its Oncology & Multispecialty segment. It also completed the sale of its Norwegian operations for $821 million, resulting in a $480 million net gain.

auto_awesomeAnalysis

This annual 10-K filing provides comprehensive audited financial results for fiscal year 2026, confirming strong performance with significant revenue and earnings growth. It details a substantial increase in the share repurchase authorization to $7.7 billion, signaling a strong commitment to capital return. Crucially, the filing elaborates on the strategic separation of the Medical-Surgical Solutions segment, including a $1.25 billion investment from Apollo Funds for a 13% minority stake, a move expected to unlock significant value. While some of this information was previously summarized in an 8-K, the 10-K provides the full audited financial context and granular details, making it highly important for investors to understand the company's financial health, strategic direction, and capital allocation plans.